Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects

NCT01206907 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The study is no longer required for the PREA for this product.

Conditions

Chronic Pain

Interventions

DRUG: oxymorphone IR

Sponsor

Endo Pharmaceuticals